多药耐药基因在大肠癌中的检测及其临床意义  

QUANTITATIVE ANALYSIS OF MDR1 GENE EXPRESSION IN PATIENTS WITH COLORECTAL CANCER

作　　者：陈立军[1] 宋廷惠[1] 蒋彦永[1] 汲言山[1] 胡美茹[1] 沈倍奋[1] 

机构地区：[1]北京军事医学科学院附属医院外科,北京解放军总医院普外科,北京军事医学科学院基础医学研究所

出　　处：《癌症》1995年第6期407-410,共4页Chinese Journal of Cancer

摘　　要：我们利用逆转录聚合酶链反应（ＲＴ－ＰＣＲ）技术定量分析了５４例大肠癌患者多药耐药基因（ＭＤＰ１）表达水平，探讨其与临床化疗的相关性。初步检测结果表明：大肠癌化疗疗效与ＭＤＲＩ的表达水平有关，未经化疗的患者ＭＤＲＩ呈低水平表达（＜０．５）；化疗后的患者ＭＤＲＩ均呈高水平表达（＞０．５），而且随着化疗疗程的增加ＭＤＲＩ的表达水平有增加的趋势（０．５～０．９７）。化疗前后ＭＤＲＩ的表达水平具有极显著的差异（Ｐ＜０．００１）；同时还发现同一病理类型分化程度不同的癌肿ＭＤＲＩ的表达水平也不同，高分化腺癌要明昆高于中、低分化腺癌（Ｐ＜０．０１）。The resistance of tumor cells to chemotherapeutic drugs is a major obstacle tosuccessful cancer chemotherapy. We have designed a highly sensitive、specific and quantitative pro-tocal for measuring the levels of MDR1 mRNA in clinical samples,based on the RT-PCR. Wehave used this assay to measure MDR1 gene expresion in 54 clinical colorectal cancer specimens,29 cases untreated and 25 treated with FAM chemotherapy. Low levels of MDR1 gene expressionwere found by RT-PCR in most untreated tumors and high levels in the treated tumors.The re-sults of the level of MDR1 gene expression in colorectal carcinomas appears to correlated withchemotherapy and may prove to be a valuable tool in the identification of individuals whose cancer-s were resistat to specific agents. The information may be useful in designing or altering chemother-apeutic protocols in these patients

关 键 词：多药耐药基因 大肠肿瘤 药物疗法 聚合酶链反应 

分 类 号：R735.340.2[医药卫生—肿瘤]